ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer

Conditions: HER2 Low Breast Carcinoma; Triple Negative Breast Cancer; Hormone-receptor-positive Breast Cancer; Hormone Receptor Positive Breast Carcinoma Interventions: Drug: ARX788; Procedure: Computed Tomography (CT); Procedure: Biospecimen Collection Sponsors: Laura Huppert, MD, BA; Ambrx, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials